172 related articles for article (PubMed ID: 36455806)
1. Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: Methodology review and benchmark.
Ling Y; Upadhyaya P; Chen L; Jiang X; Kim Y
J Biomed Inform; 2023 Jan; 137():104256. PubMed ID: 36455806
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.
Raghavan S; Josey K; Bahn G; Reda D; Basu S; Berkowitz SA; Emanuele N; Reaven P; Ghosh D
Ann Epidemiol; 2022 Jan; 65():101-108. PubMed ID: 34280545
[TBL] [Abstract][Full Text] [Related]
4. Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data.
Lipkovich I; Svensson D; Ratitch B; Dmitrienko A
Clin Trials; 2023 Aug; 20(4):380-393. PubMed ID: 37203150
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous treatment effect analysis based on machine-learning methodology.
Gong X; Hu M; Basu M; Zhao L
CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1433-1443. PubMed ID: 34716669
[TBL] [Abstract][Full Text] [Related]
6. Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials.
Sinha P; Spicer A; Delucchi KL; McAuley DF; Calfee CS; Churpek MM
EBioMedicine; 2021 Dec; 74():103697. PubMed ID: 34861492
[TBL] [Abstract][Full Text] [Related]
7. Learning end-to-end patient representations through self-supervised covariate balancing for causal treatment effect estimation.
Tesei G; Giampanis S; Shi J; Norgeot B
J Biomed Inform; 2023 Apr; 140():104339. PubMed ID: 36940895
[TBL] [Abstract][Full Text] [Related]
8. A Flexible Approach for Assessing Heterogeneity of Causal Treatment Effects on Patient Survival Using Large Datasets with Clustered Observations.
Hu L; Ji J; Liu H; Ennis R
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429621
[TBL] [Abstract][Full Text] [Related]
9. Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials.
Rigdon J; Baiocchi M; Basu S
Trials; 2018 Jul; 19(1):382. PubMed ID: 30012181
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous treatment effects analysis for social scientists: A review.
Hu A
Soc Sci Res; 2023 Jan; 109():102810. PubMed ID: 36470639
[TBL] [Abstract][Full Text] [Related]
11. Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases.
Wendling T; Jung K; Callahan A; Schuler A; Shah NH; Gallego B
Stat Med; 2018 Oct; 37(23):3309-3324. PubMed ID: 29862536
[TBL] [Abstract][Full Text] [Related]
12. Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities.
Curth A; Peck RW; McKinney E; Weatherall J; van der Schaar M
Clin Pharmacol Ther; 2024 Apr; 115(4):710-719. PubMed ID: 38124482
[TBL] [Abstract][Full Text] [Related]
13. Using the Causal Inference Framework to Support Individualized Drug Treatment Decisions Based on Observational Healthcare Data.
Meid AD; Ruff C; Wirbka L; Stoll F; Seidling HM; Groll A; Haefeli WE
Clin Epidemiol; 2020; 12():1223-1234. PubMed ID: 33173350
[TBL] [Abstract][Full Text] [Related]
14. Comparing algorithms for characterizing treatment effect heterogeneity in randomized trials.
Sun S; Sechidis K; Chen Y; Lu J; Ma C; Mirshani A; Ohlssen D; Vandemeulebroecke M; Bornkamp B
Biom J; 2024 Jan; 66(1):e2100337. PubMed ID: 36437036
[TBL] [Abstract][Full Text] [Related]
15. Real-World Evidence, Causal Inference, and Machine Learning.
Crown WH
Value Health; 2019 May; 22(5):587-592. PubMed ID: 31104739
[TBL] [Abstract][Full Text] [Related]
16. Some methods for heterogeneous treatment effect estimation in high dimensions.
Powers S; Qian J; Jung K; Schuler A; Shah NH; Hastie T; Tibshirani R
Stat Med; 2018 May; 37(11):1767-1787. PubMed ID: 29508417
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. From Real-World Patient Data to Individualized Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges.
Bica I; Alaa AM; Lambert C; van der Schaar M
Clin Pharmacol Ther; 2021 Jan; 109(1):87-100. PubMed ID: 32449163
[TBL] [Abstract][Full Text] [Related]
19. Harnessing causal forests for epidemiologic research: key considerations.
Shiba K; Inoue K
Am J Epidemiol; 2024 Jun; 193(6):813-818. PubMed ID: 38319713
[TBL] [Abstract][Full Text] [Related]
20. AIPW: An R Package for Augmented Inverse Probability-Weighted Estimation of Average Causal Effects.
Zhong Y; Kennedy EH; Bodnar LM; Naimi AI
Am J Epidemiol; 2021 Dec; 190(12):2690-2699. PubMed ID: 34268567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
